Victory Capital Management
AQST icon

Victory Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Victory Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.7K Buy
13,177
+21
+0.2% +$85 ﹤0.01% 2309
2025
Q4 		$85K Buy
13,156
+362
+3% +$2.26K ﹤0.01% 2284
2025
Q3 		$71.5K Buy
12,794
+1,862
+17% +$8.05K ﹤0.01% 2320
2025
Q2 		$36.2K Buy
10,932
+364
+3% +$1.04K ﹤0.01% 2407
2025
Q1 		$30.6K Buy
+10,568
New +$32K ﹤0.01% 2402
2024
Q4 		– Sell
-10,073
Closed -$50.2K – 2474
2024
Q3 		$50.2K Sell
10,073
-226
-2% -$879 ﹤0.01% 2392
2024
Q2 		$26.8K Buy
+10,299
New +$34.4K ﹤0.01% 2408
2020
Q2 		– Sell
-9,960
Closed -$22K – 2547
2020
Q1 		$22K Buy
+9,960
New +$37.8K ﹤0.01% 3054
2019
Q4 		– Sell
-3,148
Closed -$10K – 2667
2019
Q3 		$10K Buy
+3,148
New +$11.8K ﹤0.01% 3252
2019
Q2 		– Sell
-5,000
Closed -$35K – 1823
2019
Q1 		$35K Hold
5,000
– – ﹤0.01% 1725
2018
Q4 		$32K Hold
5,000
– – ﹤0.01% 1720
2018
Q3 		$88K Buy
+5,000
New +$82.4K ﹤0.01% 1679

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Victory Capital Management's AQST Position: Q1 2026 in Review

Victory Capital Management increased its Aquestive Therapeutics (AQST) stake by 0.16% in Q1 2026, buying an estimated $85 and bringing the position to 13,177 shares worth $54.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2309.

Victory Capital Management first reported a position in AQST in Q3 2018 and has held it in 12 quarters since. The position peaked at $88K in Q3 2018. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Victory Capital Management held 13,177 shares of Aquestive Therapeutics worth $54.7K as of Q1 2026.
  • Victory Capital Management bought 21 Aquestive Therapeutics shares in Q1 2026, an estimated $85.
  • Aquestive Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2309 holding.
  • Victory Capital Management first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 12 quarters since.
  • Victory Capital Management's Aquestive Therapeutics position peaked at $88K in Q3 2018.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.